ClinicalTrials.gg
CompletedNCT01544491Updated May 31, 2019Results posted

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

A Phase 3 interventional study of RAD001 and MMF in Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant, sponsored by Novartis Pharmaceuticals. Completed at 31 sites in 13 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2019-05-31.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Death with a site in Germany — 2 open to participants now, 6 under way, 2 of them phase 3. Death · Germany.

Started
2012
with 2 others
Phase 3
4 of 22
none open now
Registered
6th of 22
by date

Among the 22 studies in Death with a site in Germany, this one is one of 3 that started in 2012, is one of 4 in phase 3, and was the 6th registered.

Death

456 studies on the registry are indexed under Death; 86 are open to participants now.

Browse Death studies →

Open to participants now

2 of the 22 studies in Death with a site in Germany are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 59 Death studies recruiting now, 44 (75%) set no upper age limit and 8 (14%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Death with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to determine if everolimus combined with reduced exposure CNI (TAC) is efficacious and safe and will support corticosteroid elimination compared to a standard exposure CNI (TAC) + MMF + steroid regimen after paediatric kidney transplantation. An additional purpose of the study is to assess the effect of the combination of EVR and reduced exposure CNI (TAC) on renal function.

This study is part of the requirements of the Paediatric Investigational Plan approved by Paediatric Committee at the European Medicines Agency (PDCO/EMA) on September 10, 2010, and is intended to support the indication of everolimus in the prevention of acute rejection in paediatric recipients of a renal transplant.

03

Conditions studied

  • Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant

Browse trials for

Keywords

  • Paediatric kidney transplantation
  • Early MMF to everolimus conversion
  • Composite efficacy (biopsy-proven acute rejection, graft loss or death)
  • Renal function
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion criteria at baseline:

  1. Written /assent must be obtained from the parent(s) or legal guardian before any assessment is performed.
  2. Primary or secondary paediatric kidney transplant recipient aged greater than or equal to 1 year and younger than 18 years receiving a deceased donor or non-HLA identical living donor (related or unrelated) renal transplant.

Inclusion criteria at randomization:

  1. Patients on TAC + MMF + .
  2. Renal function with > 40 ml/min/1.73 m2 (Schwartz formula - abbreviated).

Exclusion Criteria:

Exclusion criteria at baseline:

  1. Recipients of kidneys from donors with known renal disease (such as diabetes nephropathy, nephrosclerosis), at the time of transplant.
  2. Recipients of a kidney with a cold ischemia time > 24 hours.
  3. History of or to any of the study drugs or to drugs of similar chemical classes, or to any of the .
  4. History of of any organ system treated or untreated, carrying possible risk of recurrence according to current guidelines (Appendix 10 of protocol).

Exclusion criteria at randomization:

  1. Use of other drugs at the time of randomization, or within 30 days or 5 half-lives prior randomization, whichever is longer.
  2. Patients with ongoing or recently (within 2 weeks prior to randomization) treated episodes of acute rejection (any grade) or a steroid resistant acute rejection at the time of randomization.
  3. Patients who experienced acute cellular rejection (Banff ≥1B) or any antibody mediated acute rejection or patients considered at high risk of antibody mediated acute rejection by the investigator assessment (e.g. presence of newly formed DSA, histological suspicion) at any time before randomization (as the DSA quantitative threshold to define high risk is not fully established, the assessment of the risk will be made after discussion between the laboratory expert and the investigator who will take into account all information available and apply best judgment).
  4. Patients with ongoing wound healing problems, wound infection requiring continued therapy or other severe surgical complication in the opinion of the investigator.
  5. Patients who are treated with drugs that are strong inducers or inhibitors of cytochrome P450 3A4 () and can not discontinue the treatment (see Appendix 6 for list of medications).
  6. Patients with nephrotic range proteinuria (protein to creatinine ratio ≥2.0 mg/mg or 200 mg/mmol (Hogg, 2003).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Investigational arm

    Conversion from MMF to everolimus plus reduced dose tacrolimus and steroids withdrawal at 6 months after transplant

    Drug: RAD001

  • Active comparator
    Control arm

    MMF continuation (in combination with tacrolimus and standard dose steroids)

    Drug: MMF

Interventions

  • DrugRAD001

    Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant

  • DrugMMF

    MMF (Cellcept®): 600mg/m2/dose twice daily (1200 mg/m2/day) in combination with tacrolimus (Prograf) and standard dose steroids

06

What researchers measure

Primary outcomes

  1. Number of Participants Having Reached the Composite Efficacy Endpoint of Biopsy-proven Acute Rejection

    To estimate the rate of the composite efficacy endpoint of biopsy-proven acute rejection (BPAR), graft loss or death at 12 months post transplantation in primary paediatric kidney transplant recipients converted at 4-6 weeks post-transplantation from MMF + standard TAC regimen and steroids, to everolimus + reduced dose TAC regimen and steroid withdrawal at 6 months, versus continuation of MMF + standard TAC regimen and steroids.

    Time frame: 12 months, 36 months

  2. To Evaluate Renal Function, Assessed by Glomerular Filtration Rate (eGFR) and Estimated by the Schwartz Formula (Abbreviated), at Month 12 and 36

    To evaluate renal function assessed by Glomerular Filtration Rate (eGFR) estimated by the Schwartz Formula (abbreviated) (Schwartz, 2009).

    Time frame: 12 months and 36 months post-transplantation

Secondary outcomes

  1. Composite Efficacy Endpoint

    To evaluate the proportion of patients with the following efficacy events: Biopsy Proven Acute Rejection (BPAR), graft loss or death. The efficacy events will be descriptively summarized by treatment group.

    Time frame: at 12 and 36 months post-transplantation

  2. To Evaluate the Severity of BPAR (Acute T-cell Mediated Rejection Only) (Banff 2009)

    T-cell mediated rejection severity : Type IA - Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells). Type IB - Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells). Type IIA - Mild to moderate intimal arteritis Type IIB - Severe intimal arteritis comprising \> 25% of the lumenal area Type III - Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)

    Time frame: month 12, month 36

  3. To Evaluate the Time to Event of BPAR

    Time to incidence of Event, given in terms of number of participants with an Event according to time interval up to 36 months

    Time frame: 36 months

  4. Incidence of Biopsy Proven Antibody Mediated Rejection.

    To evaluate the proportion of patients with the following efficacy events: biopsy proven antibody mediated rejection/Steroid resistant BPAR and BPAR treated with T cell depleting therapy.

    Time frame: at 12 and 36 months post-transplantation

  5. Chronic Allograft Nephropathy / Interstitial Fibrosis and Tubular Atrophy

    To evaluate the proportion of patients with chronic allograft nephropathy (interstitial fibrosis and tubular atrophy, IF/TA) by histopathology and its progression.The term chronic allograft nephropathy was used inappropriately in the protocol and therefore, replaced by interstitial fibrosis and tubular atrophy

    Time frame: at 12 and 36 months post-transplantation.

  6. Proteinuria (Urinary Protein/Creatinine Ratio)

    The urinary protein/creatinine ratio will be descriptively summarized by treatment group at each visit. The incidence rate of patients with proteinuria will be categorized in \<0.2 g/mg/mg, 0.2\<2.0 mg/mg and ≥ 2.0 mg/mg and summarized by treatment groups at each visit.

    Time frame: at 12 and 36 months post-transplantation

  7. Growth/Development : Weight, Height, BMI : Change From Baseline

    Evaluation of the potential effects upon the bone growth. The Z-score is a statistical tool which helps to assess data (here child growth parameters) relative to a reference or standard population. The Z-score describes the distance and direction of an observation away from the population median (or mean, however, here the median was used). A negative Z-score shows that data are lower than the median of the standard population, a positive Z-score shows that data are higher than the median of the standard population, and a Z-score of zero shows that the data are equal to the median of the standard population. The more the Z-score is distant from 0, the more expressed is for example underweight or overweight.

    Time frame: month 12 , month 36 post transplantation.

  8. Evaluation of Evolution of Renal Allograft Function Over Time

    results given as eGFR values by time interval

    Time frame: baseline, 6 months, 12 months , 24 months, 36 months

  9. To Evaluate Renal Function, Assessed by Glomerular Filtration Rate (eGFR) and Estimated by the Schwartz Formula (Extended), at Month 12

    To evaluate renal function assessed by Glomerular Filtration Rate (eGFR) estimated by the Schwartz Formula (extended) (Schwartz, 2009). Results given as change from randomization

    Time frame: 12 months post-transplantation

07

Results

Posted May 31, 2019

Participant flow

Full Analysis set (FAS) 106 enrolled and randomized patients except misrandomized Per Protocol set (PPS) 90 patients in the FAS without major protocol deviations Safety set (SAF) 106 randomized patients who received at least one dose of study drug

Participant flow — Overall Study
MilestoneEVR+rTACMMF+sTAC
Started5254
Completed4751
Not completed53
Withdrew: Withdrawal by subject32
Withdrew: Lost to follow-up01
Withdrew: Administrative problems20

Outcome measures

PrimaryNumber of Participants Having Reached the Composite Efficacy Endpoint of Biopsy-proven Acute Rejection

To estimate the rate of the composite efficacy endpoint of biopsy-proven acute rejection (BPAR), graft loss or death at 12 months post transplantation in primary paediatric kidney transplant recipients converted at 4-6 weeks post-transplantation from MMF + standard TAC regimen and steroids, to everolimus + reduced dose TAC regimen and steroid withdrawal at 6 months, versus continuation of MMF + standard TAC regimen and steroids.

Time frame:
12 months, 36 months
Reported as:
Count of participants · Participants
Number of Participants Having Reached the Composite Efficacy Endpoint of Biopsy-proven Acute Rejection
ParticipantsEVR+rTACMMF+sTAC
12 months53
36 months55
Statistical analysis
  • EVR+rTAC vs MMF+sTAC · Log Rank · p = 0.9712 · Mean difference (final values): 0.1 · 80% CI -6.6 to 6.8
  • EVR+rTAC vs MMF+sTAC · Log Rank · p = 0.9634 · Mean difference (final values): 0.2 · 80% CI -7.3 to 7.7
PrimaryTo Evaluate Renal Function, Assessed by Glomerular Filtration Rate (eGFR) and Estimated by the Schwartz Formula (Abbreviated), at Month 12 and 36

To evaluate renal function assessed by Glomerular Filtration Rate (eGFR) estimated by the Schwartz Formula (abbreviated) (Schwartz, 2009).

Time frame:
12 months and 36 months post-transplantation
Reported as:
Mean · mL/min/1.73m2
To Evaluate Renal Function, Assessed by Glomerular Filtration Rate (eGFR) and Estimated by the Schwartz Formula (Abbreviated), at Month 12 and 36
mL/min/1.73m2EVR+rTACMMF+sTAC
12 months76.7 ± 3.6671.7 ± 3.56
36 months68.1 ± 3.4567.3 ± 3.54
Statistical analysis
  • EVR+rTAC vs MMF+sTAC · t-test, 2 sided · p = 0.3455 · Mean difference (net): 5.0 · 80% CI -1.8 to 11.8
  • EVR+rTAC vs MMF+sTAC · t-test, 2 sided · p = 0.8642 · Mean difference (final values): 0.8 · 80% CI -5.5 to 7.2
SecondaryComposite Efficacy Endpoint

To evaluate the proportion of patients with the following efficacy events: Biopsy Proven Acute Rejection (BPAR), graft loss or death. The efficacy events will be descriptively summarized by treatment group.

Time frame:
at 12 and 36 months post-transplantation
Reported as:
Count of participants · Participants
Composite Efficacy Endpoint
ParticipantsEVR+rTACMMF+sTAC
month 12 composite efficacy endpoint53
graft loss 12 months00
death 12 months00
acute rejection 12 months54
treated acute rejection 12 months54
Biopsy proven acute rejection 12 months53
treated Biopsy proven acute rejection 12 months53
month 36 composite efficacy endpoint55
graft loss 36 months12
death 36 months00
acute rejection 36 months57
Biopsy proven acute rejection 36 months55
treated Biopsy proven acute rejection 36 months55
SecondaryTo Evaluate the Severity of BPAR (Acute T-cell Mediated Rejection Only) (Banff 2009)

T-cell mediated rejection severity : Type IA - Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells). Type IB - Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells). Type IIA - Mild to moderate intimal arteritis Type IIB - Severe intimal arteritis comprising \> 25% of the lumenal area Type III - Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)

Time frame:
month 12, month 36
Reported as:
Count of participants · Participants
To Evaluate the Severity of BPAR (Acute T-cell Mediated Rejection Only) (Banff 2009)
ParticipantsEVR+rTACMMF+sTAC
month 12 grade IA31
month 12 grade IB10
month 12 grade IIA02
month 12 grade IIB00
month 12 grade III00
month 36 grade IA31
month 36 grade IB20
month 36 grade IIA01
month 36 grade IIB01
month 36 grade III01
SecondaryTo Evaluate the Time to Event of BPAR

Time to incidence of Event, given in terms of number of participants with an Event according to time interval up to 36 months

Time frame:
36 months
Reported as:
Count of participants · Participants
To Evaluate the Time to Event of BPAR
ParticipantsEVR+rTACMMF+sTAC
day 1-700
day 8-1400
day 15-2810
day 29-5600
day 57-8400
day 85-15022
day 151- 24000
day 241-33012
day 331- 51001
day 511-69010
day 691-87000
day 871-105000
after day 105000
SecondaryIncidence of Biopsy Proven Antibody Mediated Rejection.

To evaluate the proportion of patients with the following efficacy events: biopsy proven antibody mediated rejection/Steroid resistant BPAR and BPAR treated with T cell depleting therapy.

Time frame:
at 12 and 36 months post-transplantation
Reported as:
Count of participants · Participants
Incidence of Biopsy Proven Antibody Mediated Rejection.
ParticipantsEVR+rTACMMF+sTAC
patients with BPAR at 12 months78
BPAR Steroid resistant,12 months10
BPAR, T Cell depleting therapy 12 months11
patients with BPAR at 36 months612
BPAR Steroid resistant,36 months12
BPAR, T Cell depleting therapy 36 months21
SecondaryChronic Allograft Nephropathy / Interstitial Fibrosis and Tubular Atrophy

To evaluate the proportion of patients with chronic allograft nephropathy (interstitial fibrosis and tubular atrophy, IF/TA) by histopathology and its progression.The term chronic allograft nephropathy was used inappropriately in the protocol and therefore, replaced by interstitial fibrosis and tubular atrophy

Time frame:
at 12 and 36 months post-transplantation.
Reported as:
Count of participants · Participants
Chronic Allograft Nephropathy / Interstitial Fibrosis and Tubular Atrophy
ParticipantsEVR+rTACMMF+sTAC
12 months33
36 months117
SecondaryProteinuria (Urinary Protein/Creatinine Ratio)

The urinary protein/creatinine ratio will be descriptively summarized by treatment group at each visit. The incidence rate of patients with proteinuria will be categorized in \<0.2 g/mg/mg, 0.2\<2.0 mg/mg and ≥ 2.0 mg/mg and summarized by treatment groups at each visit.

Time frame:
at 12 and 36 months post-transplantation
Reported as:
Count of participants · Participants
Proteinuria (Urinary Protein/Creatinine Ratio)
ParticipantsEVR+rTACMMF+sTAC
Baseline < 200mg/g12
Baseline 200 - < 2000 mg/g1212
Baseline >= 2000 mg/g1415
Month 12 < 200mg/g1928
Month 12 200 - < 2000 mg/g1311
Month 12 >= 2000 mg/g00
Month 36 < 200mg/g2323
Month 36 200 - < 2000 mg/g1011
Month 36 >= 2000 mg/g10
SecondaryGrowth/Development : Weight, Height, BMI : Change From Baseline

Evaluation of the potential effects upon the bone growth. The Z-score is a statistical tool which helps to assess data (here child growth parameters) relative to a reference or standard population. The Z-score describes the distance and direction of an observation away from the population median (or mean, however, here the median was used). A negative Z-score shows that data are lower than the median of the standard population, a positive Z-score shows that data are higher than the median of the standard population, and a Z-score of zero shows that the data are equal to the median of the standard population. The more the Z-score is distant from 0, the more expressed is for example underweight or overweight.

Time frame:
month 12 , month 36 post transplantation.
Reported as:
Mean · z score
Growth/Development : Weight, Height, BMI : Change From Baseline
z scoreEVR+rTACMMF+sTAC
Height month 120.37 ± 0.6250.20 ± 0.537
Height month 360.72 ± 1.1310.39 ± 0.776
Weight month 120.30 ± 0.7320.42 ± 0.747
Weight month 360.61 ± 0.9870.82 ± 1.268
BMI month 120.00 ± 0.7160.24 ± 0.980
BMI month 360.02 ± 0.8600.47 ± 1.231
SecondaryEvaluation of Evolution of Renal Allograft Function Over Time

results given as eGFR values by time interval

Time frame:
baseline, 6 months, 12 months , 24 months, 36 months
Reported as:
Mean · ml/min/1.73m2
Evaluation of Evolution of Renal Allograft Function Over Time
ml/min/1.73m2EVR+rTACMMF+sTAC
baseline14.2 ± 11.3813.1 ± 15.62
month 676.6 ± 28.2968.3 ± 21.02
month 1276.9 ± 21.6167.8 ± 23.57
month 2472.9 ± 28.4368.6 ± 23.26
month 3668.2 ± 21.6069.6 ± 20.01
SecondaryTo Evaluate Renal Function, Assessed by Glomerular Filtration Rate (eGFR) and Estimated by the Schwartz Formula (Extended), at Month 12

To evaluate renal function assessed by Glomerular Filtration Rate (eGFR) estimated by the Schwartz Formula (extended) (Schwartz, 2009). Results given as change from randomization

Time frame:
12 months post-transplantation
Reported as:
Mean · mL/min/1.73m2
To Evaluate Renal Function, Assessed by Glomerular Filtration Rate (eGFR) and Estimated by the Schwartz Formula (Extended), at Month 12
mL/min/1.73m2EVR+rTACMMF+sTAC
To Evaluate Renal Function, Assessed by Glomerular Filtration Rate (eGFR) and Estimated by the Schwartz Formula (Extended), at Month 124.6 ± 11.94-0.0 ± 23.92

Adverse events

Collected over up to 36 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EVR+rTAC0/52 (0%)0/52 (0%)46/52 (88.5%)
MMF+sTAC0/54 (0%)0/54 (0%)48/54 (88.9%)
Most frequent other events
Showing 10 of 60
Most frequent other events
EventEVR+rTACMMF+sTAC
NasopharyngitisInfections and infestations16/526/54
DiarrhoeaGastrointestinal disorders13/5216/54
Urinary tract infectionInfections and infestations13/5215/54
PyrexiaGeneral disorders14/5211/54
CoughRespiratory, thoracic and mediastinal disorders11/5210/54
AnaemiaBlood and lymphatic system disorders10/5211/54
HeadacheNervous system disorders10/5211/54
VomitingGastrointestinal disorders10/528/54
NeutropeniaBlood and lymphatic system disorders2/5210/54
Aphthous ulcerGastrointestinal disorders9/521/54

Baseline characteristics

Age, Customized
Age, Customized(Participants)EVR+rTACMMF+sTACTotal
1 to <11 years262753
11 <= 18 years262753
Sex/Gender, Customized
Sex/Gender, Customized(Participants)EVR+rTACMMF+sTACTotal
Male293160
Female232346
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EVR+rTACMMF+sTACTotal
Caucasian424789
Black101
Asian325
Other6511
08

Study locations

31 sites
  • Novartis Investigative Site
    Los Angeles, California 90095-1752, United States
  • Novartis Investigative Site
    Ann Arbor, Michigan 48109-0331, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63110, United States
  • Novartis Investigative Site
    Santa Fe, S3000EPV, Argentina
  • Novartis Investigative Site
    Porto Alegre, RS 90020-090, Brazil
  • Novartis Investigative Site
    São Paulo, SP 04038-002, Brazil
  • Novartis Investigative Site
    Bron Cedex, 69677, France
  • Novartis Investigative Site
    Lille, 59000, France
  • Novartis Investigative Site
    Paris cedex 15, 75015, France
  • Novartis Investigative Site
    Paris, 75019, France
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Budapest, 1082, Hungary
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Genova, GE 16147, Italy
  • Novartis Investigative Site
    Roma, ITA 00165, Italy
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Oslo, 0424, Norway
  • Novartis Investigative Site
    Warsaw, 04 730, Poland
  • Novartis Investigative Site
    Esplugues de Llobregat, Barcelona 08950, Spain
  • Novartis Investigative Site
    Stockholm, 14186, Sweden
  • Novartis Investigative Site
    Antalya, 07070, Turkey
  • Novartis Investigative Site
    London, WC1N 1EH, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
  • Novartis Investigative Site
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Publications

  • Patry C, Sauer LD, Sander A, Krupka K, Fichtner A, Brezinski J, Geissbuhler Y, Aubrun E, Grinienko A, Strologo LD, Haffner D, Oh J, Grenda R, Pape L, Topaloglu R, Weber LT, Bouts A, Kim JJ, Prytula A, Konig J, Shenoy M, Hocker B, Tonshoff B. Emulation of the control cohort of a randomized controlled trial in pediatric kidney transplantation with Real-World Data from the CERTAIN Registry. Pediatr Nephrol. 2023 May;38(5):1621-1632. doi: 10.1007/s00467-022-05777-x. Epub 2022 Oct 20. PubMed 36264431 ↗
  • Tonshoff B, Tedesco-Silva H, Ettenger R, Christian M, Bjerre A, Dello Strologo L, Marks SD, Pape L, Veldandi U, Lopez P, Cousin M, Pandey P, Meier M. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal. Am J Transplant. 2021 Jan;21(1):123-137. doi: 10.1111/ajt.16005. Epub 2020 Jun 27. PubMed 32406111 ↗

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2012 to primary completion in Oct 2016, 49 months.

Results were first posted in May 2019, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2011
First posted
Mar 6, 2012
StartActual
Aug 17, 2012
Primary completionActual
Oct 3, 2016
CompletionActual
Sep 24, 2018
Results first posted
May 31, 2019
Last update
May 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01544491
Responsible party
Sponsor
First posted
Mar 6, 2012
Start date
Aug 17, 2012
Primary completion
Oct 3, 2016
Completion
Sep 24, 2018
Results posted
May 31, 2019
Last update
May 31, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion